Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $34.00 Average PT from Brokerages

Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) have been assigned a consensus rating of “Moderate Buy” from the thirteen analysts that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, four have assigned a hold rating and eight have given a buy rating to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $34.00.

ARCT has been the subject of a number of recent analyst reports. Wall Street Zen downgraded Arcturus Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, December 13th. Citigroup dropped their price target on shares of Arcturus Therapeutics from $9.00 to $7.00 and set a “neutral” rating for the company in a research report on Tuesday, January 6th. Roth Mkm started coverage on shares of Arcturus Therapeutics in a research note on Thursday, January 22nd. They issued a “buy” rating and a $20.00 price target on the stock. Piper Sandler lowered their price objective on shares of Arcturus Therapeutics from $140.00 to $72.00 and set an “overweight” rating for the company in a research report on Tuesday, November 11th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Arcturus Therapeutics in a research report on Wednesday, January 21st.

Hedge Funds Weigh In On Arcturus Therapeutics

Several hedge funds have recently bought and sold shares of the company. Osaic Holdings Inc. boosted its holdings in Arcturus Therapeutics by 51.8% during the 2nd quarter. Osaic Holdings Inc. now owns 2,163 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 738 shares during the period. BNP Paribas Financial Markets lifted its position in shares of Arcturus Therapeutics by 163.4% during the second quarter. BNP Paribas Financial Markets now owns 4,169 shares of the biotechnology company’s stock worth $54,000 after purchasing an additional 2,586 shares in the last quarter. Mercer Global Advisors Inc. ADV purchased a new position in shares of Arcturus Therapeutics in the fourth quarter valued at approximately $64,000. Intech Investment Management LLC purchased a new position in shares of Arcturus Therapeutics in the fourth quarter valued at approximately $70,000. Finally, CANADA LIFE ASSURANCE Co grew its holdings in shares of Arcturus Therapeutics by 65.1% in the fourth quarter. CANADA LIFE ASSURANCE Co now owns 12,009 shares of the biotechnology company’s stock valued at $73,000 after purchasing an additional 4,737 shares in the last quarter. Institutional investors and hedge funds own 94.54% of the company’s stock.

Arcturus Therapeutics Stock Performance

Shares of Arcturus Therapeutics stock opened at $8.23 on Monday. The stock has a 50 day moving average of $7.20 and a 200 day moving average of $11.61. The firm has a market capitalization of $233.81 million, a price-to-earnings ratio of -3.35 and a beta of 2.39. Arcturus Therapeutics has a fifty-two week low of $5.85 and a fifty-two week high of $24.17.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.